Clinical data
ATC code none
CAS Number 219810-59-0 YesY
PubChem (CID) 6433106
ChemSpider 4938294 N
UNII 856DX0KJ84 YesY
ECHA InfoCard 100.107.752
Chemical and physical data
Formula C11H23N
Molar mass 169.307 g/mol
3D model (Jmol) Interactive image
 NYesY (what is this?)  (verify)

Neramexane is a drug related to memantine,[1] which acts as an NMDA antagonist[2] and has neuroprotective effects.[3] It is being developed for various possible applications, including treatment of tinnitus,[4][5] Alzheimer's disease,[6] drug addiction[7] and as an analgesic.[8] Animal studies have also suggested antidepressant[9] and nootropic[10] actions, so there are a wide range of potential applications this drug may be used for. It also acts as a nicotinic acetylcholine receptor antagonist.[11]

A clinical trial found that doses of 50mg and above safely improved tinnitus scores over 16 weeks.[12]

See also


  1. Gilling, K; Jatzke, C; Wollenburg, C; Vanejevs, M; Kauss, V; Jirgensons, A; Parsons, CG (2007). "A novel class of amino-alkylcyclohexanes as uncompetitive, fast, voltage-dependent, N-methyl-D-aspartate (NMDA) receptor antagonists--in vitro characterization". Journal of Neural Transmission. 114 (12): 1529–37. doi:10.1007/s00702-007-0792-7. PMID 17728997.
  2. Danysz, W; Parsons, CG; Jirgensons, A; Kauss, V; Tillner, J (2002). "Amino-alkyl-cyclohexanes as a novel class of uncompetitive NMDA receptor antagonists". Current Pharmaceutical Design. 8 (10): 835–43. doi:10.2174/1381612024607117. PMID 11945134.
  3. Danysz, W; Parsons, CG (Mar 2002). "Neuroprotective potential of ionotropic glutamate receptor antagonists". Neurotoxicity Research. 4 (2): 119–26. doi:10.1080/10298420290015872. PMID 12829411.
  4. Clinical trial number NCT00405886 for "Neramexane for Tinnitus" at
  5. Clinical trial number NCT00739635 for "Efficacy, Safety and Tolerability of Neramexane in Patients With Subjective Tinnitus" at
  6. Rammes, G; Schierloh, A (Feb 2006). "Neramexane (merz pharmaceuticals/forest laboratories)". IDrugs. 9 (2): 128–35. PMID 16523403.
  7. Kotlinska, J; Biala, G; Rafalski, P; Bochenski, M; Danysz, W (Oct 2004). "Effect of neramexane on ethanol dependence and reinforcement". European Journal of Pharmacology. 503 (1-3): 95–8. doi:10.1016/j.ejphar.2004.09.036. PMID 15496302.
  8. Klein, T; Magerl, W; Hanschmann, A; Althaus, M; Treede, RD (Jan 2008). "Antihyperalgesic and analgesic properties of the N-methyl-D-aspartate (NMDA) receptor antagonist neramexane in a human surrogate model of neurogenic hyperalgesia". European Journal of Pain. 12 (1): 17–29. doi:10.1016/j.ejpain.2007.02.002. PMID 17449306.
  9. Kos, T; Legutko, B; Danysz, W; Samoriski, G; Popik, P (Sep 2006). "Enhancement of antidepressant-like effects but not brain-derived neurotrophic factor mRNA expression by the novel N-methyl-D-aspartate receptor antagonist neramexane in mice". Journal of Pharmacology and Experimental Therapeutics. 318 (3): 1128–36. doi:10.1124/jpet.106.103697. PMID 16740621.
  10. Zoladz, PR; Campbell, AM; Park, CR; Schaefer, D; Danysz, W; Diamond, DM (Oct 2006). "Enhancement of long-term spatial memory in adult rats by the noncompetitive NMDA receptor antagonists, memantine and neramexane". Pharmacology, Biochemistry and Behaviour. 85 (2): 298–306. doi:10.1016/j.pbb.2006.08.011. PMID 17045636.
  11. Plazas PV, Savino J, Kracun S, et al. (July 2007). "Inhibition of the alpha9alpha10 nicotinic cholinergic receptor by neramexane, an open channel blocker of N-methyl-D-aspartate receptors". European Journal of Pharmacology. 566 (1-3): 11–9. doi:10.1016/j.ejphar.2007.03.026.
  12. "A randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of neramexane in patients with moderate to severe subjective tinnitus.". BMC Ear, Nose and Throat Disorders. 11: 1. Jan 2011. doi:10.1186/1472-6815-11-1. PMID 21223542.

This article is issued from Wikipedia - version of the 4/2/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.